Alan Levy, PhD, Chief Executive Officer
Prior to Incline, Dr. Levy was a Venture Partner with Frazier Healthcare Ventures since 2007. Prior to Frazier he was President and CEO of Northstar Neuroscience, a company developing innovative therapies for neurological diseases and disorders, President and CEO of Heartstream (sold to Hewlett-Packard), a company that developed, manufactured, and marketed an innovative automatic external defibrillator, and President of Heart Technology (sold to Boston Scientific), a company that developed, manufactured, and marketed devices for removing plaque from coronary arteries. Previously, Dr. Levy was Vice President of Research and New Business Development and a member of the Board of the Ethicon division of Johnson & Johnson. He currently serves on the board of Barosense, Intuitive Surgical (Nasdaq ISRG), Orthocon, and Proteus Biomedical. He received his B.S. in chemistry from City University of New York and his Ph.D. in organic chemistry from Purdue University.
David Socks, President and Chief Operating Officer
Prior to Incline, Mr. Socks was Senior Vice President, Corporate Development and Strategy of Cadence Pharmaceuticals, which he co-founded in 2004. He also previously served as Vice President, Business Development and Chief Financial Officer of Cadence. From 2000-2004, Mr. Socks was a Venture Partner at Windamere Venture Partners where he co-founded five biopharmaceutical and three medical device companies. Previously, he worked at Neurocrine Biosciences, EFO Holdings, and Kaiser Associates. Mr. Socks holds a B.S. in business administration from Georgetown University and an M.B.A. from Stanford University.
Patti Oto, RPh, Senior Vice President, Regulatory Affairs and Quality Assurance
Prior to Incline, Ms. Oto was Vice President of Regulatory and Quality at Onyx Pharmaceuticals where she managed the regulatory and quality activities for a marketed product and several pipeline products. Previously, she worked in roles of increasing responsibilities in quality and regulatory at Corgentech (Anesiva), Coulter Pharmaceuticals (Corixa, GlaxoSmithKline), Genentech, and Syntex. Ms. Oto has led global regulatory submissions in support of marketing authorizations for biologics, drugs and drug/device combination products in several therapeutic areas including cardiovascular, metabolics, oncology, and pain. She received her B.S. in Pharmacy from the University of New Mexico.
Brad Phipps, PhD, Senior Vice President and Chief Scientific Officer
Prior to Incline, Dr. Phipps directed the development of novel transdermal drug delivery systems at Johnson & Johnson as Vice President, Drug Device Research and Vice President, Biomedical Engineering. He held similar positions at ALZA Corporation where he was most recently Vice President, Transdermal R&D. Dr. Phipps began his career in medical technology at Medtronic where he studied the transport of ionic drugs across human skin using an applied electric potential. He received his Ph.D. in Materials Science and Engineering from Northwestern University after completing his B.S. in the same discipline at the University of Utah.
Mike Ramsay, Senior Vice President, Manufacturing and Supply Operations
Prior to Incline, Mr. Ramsay was Senior Vice President, Manufacturing Operations at Cell Genesys with responsibility for three GMP manufacturing facilities. Prior to joining Cell Genesys, he served as Vice President, Transdermal Manufacturing at ALZA Corporation. Mr. Ramsay has also held various positions with SEQUUS Pharmaceuticals, including Vice President, Manufacturing Operations, as well as various positions at Syntex Corporation focusing on manufacturing, product development and regulatory affairs. He holds a Bachelor of Pharmacy degree from the University of Nottingham in the United Kingdom.
John Tucker, Senior Vice President and Chief Commercial Officer
Prior to Incline, Mr. Tucker was Vice President, Commercial Operations at AMAG Pharmaceuticals where he was responsible for all sales and marketing activities with a primary focus on the hospital sector. Previously, he was President, U.S. Operations at Basilea Pharmaceuticals where he developed the commercial strategy and organization for the planned launch of a hospital-focused product. Prior to Basilea, Mr. Tucker was Executive Vice President, Sales and Marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS, and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an M.B.A. from New Hampshire College.
Nitin Joshi, PhD, Vice President, Product Development
Prior to Incline, Dr. Joshi was Director, Drug-Device R&D at Johnson & Johnson in a group responsible for developing combination products, including IONSYS™. He also made significant contributions in process scale-up and approval of Jurnista®, an oral controlled release product for pain relief. Previously, Dr. Joshi worked in pulmonary product development as a Senior Scientist at Elan and Group Leader at Alkermes. He received his B.S. in Chemical Engineering from UDCT, Mumbai followed by a Ph.D. in Chemical Engineering from Clemson University.
John Lemke, Vice President, Engineering
Prior to joining Incline, Mr. Lemke was Director of Electro-Mechanical Design and Development at Johnson & Johnson responsible for next generation IONSYS development. Prior to Johnson & Johnson, he was Vice President, Engineering at Fovioptics, a venture-backed medical device company developing a non-invasive measurement of blood glucose based on retinal measurements. Previously, Mr. Lemke held multiple technical and management positions at LifeScan where he staffed and led cross-functional product development teams and engineering and R&D departments in the development of glucose monitoring systems for home and hospital use. He has a B.S. in Physics from the University of California at Berkeley.